Evommune, Inc. EVMN 深 滬
已收盤 03-27 16:00:00 美东时间
22.18
-1.490
-6.29%
華盛通- 最 高23.625
- 今 開23.51
- 成交量 20.11万股
- 最 低 22.18
- 昨 收 23.67
- 總市值 7.99亿
- 52周最高 33.20
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 13.885
- 委 比 60.00%
- 總股本 3601.84万
- 歷史最高 33.20
- 量 比 0.37
- 振 幅 6.10%
- 歷史最低 13.885
- 每 手 1
- 風險率 3.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright & Co, Stifel, BTIG, Goldman Sachs made changes.
03-18 20:19
Clear Street Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $53
Clear Street analyst Kaveri Pohlman initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $53.
03-18 17:25
Evommune shares are trading higher. The company reported Q4 financial results.
Evommune shares are trading higher. The company reported Q4 financial results.
03-07 01:36
美股牛股 | 生物技术公司EVMN飙涨超70%！新药用于治疗特应性皮炎的临床试验取得积极成果；ICHR涨超32%
生物技术公司EVMN飙涨超70%！新药用于治疗特应性皮炎的临床试验取得积极成果；ICHR涨超32%，Q4收入2.24亿美元超预期>>
02-11 15:44
美股大行评级 | 安森美半导体获多家大行调目标价；BD医疗、Dynatrace、Monday、Regenxbio遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持内克塔治疗"买入"评级，目标价从135美元升至165美元；BTIG：维持内克塔治疗"买入"评级，目标价从118美元升至151美元
02-11 11:02
Evommune's Stock Surges On Strong Results For New Eczema Drug
Evommune shares jumped after its mid-stage trial showed strong skin improvement and good safety for EVO301 in patients with moderate to severe eczema.
02-11 01:29
Datadog, Spotify, Marriott, Ferrari And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining around 200 points on Tuesda...
02-10 23:56
Evommune Reports Top-Line Results From Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial Evaluating EVO301; Trial Met Primary Efficacy Endpoint At Week 12
- Trial met primary efficacy endpoint at week 12- EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo- 33% placebo-adjusted improvement in EASI at week 12- 23% of EVO301
02-10 20:35
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
